Trial · NCT07122102
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | HbA1c | From enrollment to the end of treatment at 12 weeks | The difference in HbA1c from the baseline |
| Secondary | FPG (Fasting plasma glucose) | From enrollment to the end of treatment at 12 weeks | The difference in FPG from the baseline |
| Secondary | 2h-PPG (2-hour postprandial glucose) | From enrollment to the end of treatment at 12 weeks | The difference in 2h-PPG from the baseline |
| Secondary | Fasting C-peptide | From enrollment to the end of treatment at 12 weeks | The difference in fasting C-peptide from the baseline |
| Secondary | Insulin sensitivity | From enrollment to the end of treatment at 12 weeks | The difference in insulin sensitivity from the baseline |
| Secondary | Islet function | From enrollment to the end of treatment at 12 weeks | The difference in Islet function from the baseline |
| Secondary | Body weight | From enrollment to the end of treatment at 12 weeks | The difference in body weight from the baseline |
| Secondary | Intestinal microbial composition and functional characteristics | From enrollment to the end of treatment at 12 weeks | The difference in intestinal microbial composition and functional characteristics from the baseline |
| Secondary | Incidence of hypoglycemia | From enrollment to the end of safety visitation at 13 weeks | The percentage of subjects who experienced any investigator-defined hypoglycemic adverse event |
| Secondary | Gastrointestinal adverse events | From enrollment to the end of safety visitation at 13 weeks | The percentage of subjects who experienced any investigator-defined gastrointestinal adverse events adverse event |
| Secondary | Other adverse events | From enrollment to the end of safety visitation at 13 weeks | The percentage of subjects who experienced any investigator-defined adverse event |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07122102/registered